Complement in immune and inflammatory disorders: Therapeutic interventions

Journal of Immunology

Volumn 190, Issue 8, 2013, Pages 3839-3847

  Ricklin, Daniel ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADC 1004; AL 78898A; AMY 101; AMY 201; AMY 301; APL 1; ARC 1905; BIKACIOMAB; CACP 29; CCX 168; CETOR; COMPLEMENT; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C5; COMPLEMENT INHIBITOR; ECULIZUMAB; HC 3 1496; IFX 1; IMMUNOMODULATING AGENT; LECTIN PATHWAY INHIBITOR; LFG 316; MEDI 7814; NAFAMSTAT; NAFAMSTAT MESILATE; NM 9308; NM 9401; NN 8209; NOX D 19; OMS 721; TA 106; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; ANCA ASSOCIATED VASCULITIS; ASTHMA; CHOROIDITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLEMENT ACTIVATION; DISEASE COURSE; DRUG EFFICACY; HEART INFARCTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY DISEASE; INJURY; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIA; NONHUMAN; PANCREATITIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REPERFUSION INJURY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; TREATMENT RESPONSE; UVEITIS;

ANIMALS; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; INFLAMMATION MEDIATORS;

EID: 84875990477     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203200     Document Type: Review

References (91)

1. Drews, J. 2004. Paul Ehrlich: magister mundi. Nat. Rev. Drug Discov. 3: 797-801.
2. Hussell, T. 2012. Immune modulatory strategies: a playground with a swing and a seesaw. Expert Rev. Anti Infect. Ther. 10: 249-251.
3. Ricklin, D., and J. D. Lambris. 2013. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190: 3831-3838.
4. Markiewski, M. M., and J. D. Lambris. 2007. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171: 715-727.
5. Zeerleder, S. 2011. C1-inhibitor: more than a serine protease inhibitor. Semin. Thromb. Hemost. 37: 362-374.
6. Lu, F., S. M. Fernandes, and A. E. Davis, III. 2013. The effect of C1 inhibitor on myocardial ischemia and reperfusion injury. Cardiovasc. Pathol. 22: 75-80.
7. Tillou, X., N. Poirier, S. Le Bas-Bernardet, J. Hervouet, D. Minault, K. Renaudin, F. Vistoli, G. Karam, M. Daha, J. P. Soulillou, and G. Blancho. 2010. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int. 78: 152-159.
8. Koulmanda, M., M. E. Uknis, and T. B. Strom. 2012. C1 esterase inhibitor reverses invasive insulitis and hyperglycemia in a model of type 1 diabetes. In XXIV International Complement Workshop, October 10 - 15, 2012. Aegean Conferences, Chania, Greece.
9. Schmidtko, J., S. Peine, Y. El-Housseini, M. Pascual, and P. Meier. 2013. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am. J. Kidney Dis. 61: 289-299.
10. Orth-Höller, D., M. Riedl, and R. Würzner. 2011. Inhibition of terminal complement activation in severe Shiga toxin-associated HUS - perfect example for a fast track from bench to bedside. EMBO Mol Med 3: 617-619.
11. Qu, H., D. Ricklin, and J. D. Lambris. 2009. Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 47: 185-195.
12. Subasinghe, N. L., E. Khalil, J. M. Travins, F. Ali, S. K. Ballentine, H. R. Hufnagel, W. Pan, K. Leonard, R. F. Bone, R. M. Soll, et al. 2012. Design and synthesis of polyethylene glycol-modified biphenylsulfonyl-thiophene- carboxamidine inhibitors of the complement component C1s. Bioorg. Med. Chem. Lett. 22: 5303-5307.
13. Subasinghe, N. L., J. M. Travins, F. Ali, H. Huang, S. K. Ballentine, J. J. Marugán, E. Khalil, H. R. Hufnagel, R. F. Bone, R. L. DesJarlais, et al. 2006. A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s. Bioorg. Med. Chem. Lett. 16: 2200-2204.
14. Duvall, M. R., H. Y. Hwang, and R. J. Boackle. 2010. Specific inhibition of the classical complement pathway with an engineered single-chain Fv to C1q globular heads decreases complement activation by apoptotic cells. Immunobiology 215: 395-405.
15. Dempulos, G. A., T. Dudler, and W. J. Schwaeble, inventors; Omeros Corporation, University of Leicester, assignees. Methods for treating conditions associated with MASP-2 dependent complement activation. U.S. Patent Application 13/441,827, Publication No. US20120258095 A1. 2012, Oct 11.
16. Schwaeble, W. J., N. J. Lynch, J. E. Clark, M. Marber, N. J. Samani, Y. M. Ali, T. Dudler, B. Parent, K. Lhotta, R. Wallis, et al. 2011. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. USA 108: 7523-7528.
17. Héja, D., V. Harmat, K. Fodor, M. Wilmanns, J. Dobó, K. A. Kékesi, P. Závodszky, P. Gál, and G. Pál. 2012. Monospecific inhibitors show that both mannan-binding lectin-associated serine protease-1 (MASP-1) and -2 are essential for lectin pathway activation and reveal structural plasticity of MASP-2. J. Biol. Chem. 287: 20290-20300.
18. Pavlov, V. I., M. O. Skjoedt, Y. Siow Tan, A. Rosbjerg, P. Garred, and G. L. Stahl. 2012. Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. Circulation 126: 2227-2235.
19. Harboe, M., G. Ulvund, L. Vien, M. Fung, and T. E. Mollnes. 2004. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 138: 439-446.
20. Ricklin, D., and J. D. Lambris. 2013. Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 734: 1-22.
21. Kourtzelis, I., M. M. Markiewski, M. Doumas, S. Rafail, K. Kambas, I. Mitroulis, S. Panagoutsos, P. Passadakis, V. Vargemezis, P. Magotti, et al. 2010. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 116: 631-639.
22. Silasi-Mansat, R., H. Zhu, N. I. Popescu, G. Peer, G. Sfyroera, P. Magotti, L. Ivanciu, C. Lupu, T. E. Mollnes, F. B. Taylor, et al. 2010. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116: 1002-1010.
23. Chi, Z. L., T. Yoshida, J. D. Lambris, and T. Iwata. 2010. Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv. Exp. Med. Biol. 703: 127-135.
24. Qu, H., D. Ricklin, H. Bai, H. Chen, E. S. Reis, M. Maciejewski, A. Tzekou, R. A. Deangelis, R. R. Resuello, F. Lupu, et al. 2012. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced phar-macokinetic properties. Immunobiology. In press.
25. Katschke, K. J., Jr., S. Stawicki, J. Yin, M. Steffek, H. Xi, L. Sturgeon, P. E. Hass, K. M. Loyet, L. Deforge, Y. Wu, et al. 2009. Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J. Biol. Chem. 284: 10473-10479.
26. Lindorfer, M. A., A. W. Pawluczkowycz, E. M. Peek, K. Hickman, R. P. Taylor, and C. J. Parker. 2010. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 115: 2283-2291.
27. Katschke, K. J., Jr., P. Wu, R. Ganesan, R. F. Kelley, M. A. Mathieu, P. E. Hass, J. Murray, D. Kirchhofer, C. Wiesmann, and M. van Lookeren Campagne. 2012. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J. Biol. Chem. 287: 12886-12892.
28. Thurman, J. M., D. M. Kraus, G. Girardi, D. Hourcade, H. J. Kang, P. A. Royer, L. M. Mitchell, P. C. Giclas, J. Salmon, G. Gilkeson, and V. M. Holers. 2005. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol. Immunol. 42: 87-97.
29. Kimura, Y., L. Zhou, T. Miwa, and W. C. Song. 2010. Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury. J. Clin. Invest. 120: 3545-3554.
30. Zhou, H. F., H. Yan, C. M. Stover, T. M. Fernandez, S. Rodriguez de Cordoba, W. C. Song, X. Wu, R. W. Thompson, W. J. Schwaeble, J. P. Atkinson, et al. 2012. Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm. Proc. Natl. Acad. Sci. USA 109: E415-E422.
31. Vogel, C. W., and D. C. Fritzinger. 2010. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon 56: 1198-1222.
32. Fritzinger, D. C., R. Dean, C. Meschter, K. Wong, R. Halter, J. Borlak, W. D. St John, and C. W. Vogel. 2010. Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration. Adv. Exp. Med. Biol. 703: 151-162.
33. Chen Song, S., S. Zhong, Y. Xiang, J. H. Li, H. Guo, W. Y. Wang, Y. L. Xiong, X. C. Li, S. Chen Shi, X. P. Chen, and G. Chen. 2011. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am. J. Transplant. 11: 2057-2066.
34. Ricklin, D. 2012. Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology 217: 1057-1066.
35. Li, J. S., J. Jaggers, and P. A. Anderson. 2006. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev. Cardiovasc. Ther. 4: 649-654.
36. Rioux, P. 2001. TP-10 (AVANT Immunotherapeutics). Curr. Opin. Investig. Drugs 2: 364-371.
37. Smith, R. A. 2002. Targeting anticomplement agents. Biochem. Soc. Trans. 30: 1037-1041.
38. Sacks, S., J. Karegli, C. A. Farrar, E. Asgari, W. Schwaeble, W. Zhou, and R. A. Smith. 2013. Targeting complement at the time of transplantation. Adv. Exp. Med. Biol. 734: 247-255.
39. Holers, V. M., B. Rohrer, and S. Tomlinson. 2013. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv. Exp. Med. Biol. 734: 137-154.
40. Fridkis-Hareli, M., M. Storek, I. Mazsaroff, A. M. Risitano, A. S. Lundberg, C. J. Horvath, and V. M. Holers. 2011. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 118: 4705-4713.
41. Risitano, A. M., R. Notaro, C. Pascariello, M. Sica, L. del Vecchio, C. J. Horvath, M. Fridkis-Hareli, C. Selleri, M. A. Lindorfer, R. P. Taylor, et al. 2012. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 119: 6307-6316.
42. Rohrer, B., B. Coughlin, M. Bandyopadhyay, and V. M. Holers. 2012. Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J. Ocul. Pharmacol. Ther. 28: 402-409.
43. Holers, M., N. Banda, G. Mehta, M. Fridkis-Hareli, E. Or, M. Storek, R. Altman, K. Johnson, and S. Katti. 2012. The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer models and acts by CR2-dependent targeting of CR1 regulatory activity. Immunobiology 217: 1210.
44. Schmidt, C. Q., H. Bai, Z. Lin, A. M. Risitano, P. N. Barlow, D. Ricklin, and J. D. Lambris. 2012. Rational engineering of a novel complement regulator-based therapeutic affords triple targeting of host surfaces and pathway-specific inhibition of complement activation. Immunobiology 217: 1197.
45. Lambris, J. D., D. Ricklin, and B. V. Geisbrecht. 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6: 132-142.
46. Wu, Y. Q., H. Qu, G. Sfyroera, A. Tzekou, B. K. Kay, B. Nilsson, K. Nilsson Ekdahl, D. Ricklin, and J. D. Lambris. 2011. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J. Immunol. 186: 4269-4277.
47. Nilsson, P. H., K. N. Ekdahl, P. U. Magnusson, H. Qu, H. Iwata, D. Ricklin, J. Hong, J. D. Lambris, B. Nilsson, and Y. Teramura. 2013. Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials 34: 985-994.
48. Woodruff, T. M., K. S. Nandakumar, and F. Tedesco. 2011. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48: 1631-1642.
49. Frei, Y., J. D. Lambris, and B. Stockinger. 1987. Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol. Cell. Probes 1: 141-149.
50. Strey, C. W., M. Markiewski, D. Mastellos, R. Tudoran, L. A. Spruce, L. E. Greenbaum, and J. D. Lambris. 2003. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J. Exp. Med. 198: 913-923.
51. Wang, Q., A. L. Rozelle, C. M. Lepus, C. R. Scanzello, J. J. Song, D. M. Larsen, J. F. Crish, G. Bebek, S. Y. Ritter, T. M. Lindstrom, et al. 2011. Identification of a central role for complement in osteoarthritis. Nat. Med. 17: 1674-1679.
52. Wang, Y., S. A. Rollins, J. A. Madri, and L. A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92: 8955-8959.
53. Rinder, C. S., H. M. Rinder, B. R. Smith, J. C. Fitch, M. J. Smith, J. B. Tracey, L. A. Matis, S. P. Squinto, and S. A. Rollins. 1995. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J. Clin. Invest. 96: 1564-1572.
54. Smith, P. K., S. K. Shernan, J. C. Chen, M. Carrier, E. D. Verrier, P. X. Adams, T. G. Todaro, L. H. Muhlbaier, and J. H. Levy; PRIMO-CABG II Investigators. 2011. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J. Thorac. Cardiovasc. Surg. 142: 89-98.
55. Testa, L., W. J. Van Gaal, R. Bhindi, G. G. Biondi-Zoccai, A. Abbate, P. Agostoni, I. Porto, F. Andreotti, F. Crea, and A. P. Banning. 2008. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J. Thorac. Cardiovasc. Surg. 136: 884-893.
56. Verrier, E. D., S. K. Shernan, K. M. Taylor, F. Van de Werf, M. F. Newman, J. C. Chen, M. Carrier, A. Haverich, K. J. Malloy, P. X. Adams, et al; PRIMO-CABG Investigators. 2004. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 291: 2319-2327.
57. Ferraresso, M., P. Macor, M. Valente, M. Della Barbera, F. D'Amelio, O. Borghi, E. Raschi, P. Durigutto, P. Meroni, and F. Tedesco. 2008. Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. Transplantation 86: 1445-1451.
58. Macor, P., P. Durigutto, L. De Maso, C. Garrovo, S. Biffi, A. Cortini, F. Fischetti, D. Sblattero, C. Pitzalis, R. Marzari, and F. Tedesco. 2012. Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis Rheum. 64: 2559-2567.
59. Cousins, S. W.; Ophthotech Study Group. 2010. Targeting complement factor 5 in combination with vascular endothelial growth factor (VEGF) inhibition for neo-vascular age related macular degeneration (AMD): results of a phase 1 study. Invest. Ophthalmol. Vis. Sci. 51: 1251 (Abstr.).
60. Bestebroer, J., P. C. Aerts, S. H. Rooijakkers, M. K. Pandey, J. Köhl, J. A. van Strijp, and C. J. de Haas. 2010. Functional basis for complement evasion by staphylococcal superantigen-like 7. Cell. Microbiol. 12: 1506-1516.
61. Barratt-Due, A., E. B. Thorgersen, J. K. Lindstad, A. Pharo, O. Lissina, J. D. Lambris, M. A. Nunn, and T. E. Mollnes. 2011. Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J. Immunol. 187: 4913-4919.
62. Hepburn, N. J., A. S. Williams, M. A. Nunn, J. C. Chamberlain-Banoub, J. Hamer, B. P. Morgan, and C. L. Harris. 2007. In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J. Biol. Chem. 282: 8292-8299.
63. Bora, N. S., S. Kaliappan, P. Jha, Q. Xu, B. Sivasankar, C. L. Harris, B. P. Morgan, and P. S. Bora. 2007. CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J. Immunol. 178: 1783-1790.
64. Cashman, S. M., K. Ramo, and R. Kumar-Singh. 2011. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS ONE 6: e19078.
65. Czermak, B. J., V. Sarma, C. L. Pierson, R. L. Warner, M. Huber-Lang, N. M. Bless, H. Schmal, H. P. Friedl, and P. A. Ward. 1999. Protective effects of C5a blockade in sepsis. Nat. Med. 5: 788-792.
66. Okada, N., M. Imai, A. Okada, F. Ono, and H. Okada. 2012. HMGB1 release by C5a anaphylatoxin is an effective target for sepsis treatment. Clin. Exp. Pharmacol. 2: 1000114.
67. Tokodai, K., M. Goto, A. Inagaki, W. Nakanishi, N. Ogawa, K. Satoh, N. Kawagishi, S. Sekiguchi, B. Nilsson, N. Okada, et al. 2010. Attenuation of crosstalk between the complement and coagulation cascades by C5a blockade improves early outcomes after intraportal islet transplantation. Transplantation 90: 1358-1365.
68. Köhl, J. 2006. Drug evaluation: the C5a receptor antagonist PMX-53. Curr. Opin. Mol. Ther. 8: 529-538.
69. Vergunst, C. E., D. M. Gerlag, H. Dinant, L. Schulz, M. Vinkenoog, T. J. Smeets, M. E. Sanders, K. A. Reedquist, and P. P. Tak. 2007. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford) 46: 1773-1778.
70. Fonseca, M. I., R. R. Ager, S. H. Chu, O. Yazan, S. D. Sanderson, F. M. LaFerla, S. M. Taylor, T. M. Woodruff, and A. J. Tenner. 2009. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J. Immunol. 183: 1375-1383.
71. Breivik, T., Y. Gundersen, P. Gjermo, S. M. Taylor, T. M. Woodruff, and P. K. Opstad. 2011. Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats. J. Periodontal Res. 46: 643-647.
72. Jain, U., T. M. Woodruff, and A. W. Stadnyk. 2013. The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10. Br. J. Pharmacol. 168: 488-501.
73. van der Pals, J., S. Koul, P. Andersson, M. Götberg, J. F. Ubachs, M. Kanski, H. Arheden, G. K. Olivecrona, B. Larsson, and D. Erlinge. 2010. Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovasc. Disord. 10: 45.
74. Mathieu, M. C., N. Sawyer, G. M. Greig, M. Hamel, S. Kargman, Y. Ducharme, C. K. Lau, R. W. Friesen, G. P. O'Neill, F. G. Gervais, and A. G. Therien. 2005. The C3a receptor antagonist SB 290157 has agonist activity. Immunol. Lett. 100: 139-145.
75. Garrett, M. C., M. L. Otten, R. M. Starke, R. J. Komotar, P. Magotti, J. D. Lambris, M. A. Rynkowski, and E. S. Connolly. 2009. Synergistic neuro-protective effects of C3a and C5a receptor blockade following intracerebral hemorrhage. Brain Res. 1298: 171-177.
76. Lim, J., A. Iyer, J. Y. Suen, V. Seow, R. C. Reid, L. Brown, and D. P. Fairlie. 2013. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB J. 27: 822-831.
77. Risitano, A. M. 2012. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 217: 1080-1087.
78. Alfinito, F., G. Ruggiero, M. Sica, A. Udhayachandran, V. Rubino, R. D. Pepa, A. T. Palatucci, M. Annunziatella, R. Notaro, A. M. Risitano, and G. Terrazzano. 2012. Eculizumab treatment modifies the immune profile of PNH patients. Immunobiology 217: 698-703.
79. Hill, A., P. Hillmen, S. J. Richards, D. Elebute, J. C. Marsh, J. Chan, C. F. Mojcik, and R. P. Rother. 2005. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 106: 2559-2565.
80. Röth, A., C. Hock, A. Konik, S. Christoph, and U. Dührsen. 2011. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena. Int. J. Hematol. 93: 704-714.
81. S Reis, E., D. A. Falcão, and L. Isaac. 2006. Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand. J. Immunol. 63: 155-168.
82. Skattum, L., M. van Deuren, T. van der Poll, and L. Truedsson. 2011. Complement deficiency states and associated infections. Mol. Immunol. 48: 1643-1655.
83. von Köckritz-Blickwede, M., S. Konrad, S. Foster, J. E. Gessner, and E. Medina. 2010. Protective role of complement C5a in an experimental model of Staphylo-coccus aureus bacteremia. J. Innate Immun. 2: 87-92.
84. Lachmann, P. J., and R. A. Smith. 2009. Taking complement to the clinic: has the time finally come? Scand. J. Immunol. 69: 471-478.
85. Atkinson, C., H. Song, B. Lu, F. Qiao, T. A. Burns, V. M. Holers, G. C. Tsokos, and S. Tomlinson. 2005. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J. Clin. Invest. 115: 2444-2453.
86. Barratt-Due, A., S. E. Pischke, O. L. Brekke, E. B. Thorgersen, E. W. Nielsen, T. Espevik, M. Huber-Lang, and T. E. Mollnes. 2012. Bride and groom in systemic inflammation: the bells ring for complement and Toll in cooperation. Immunobi-ology 217: 1047-1056.
87. Brekke, O. L., C. Waage, D. Christiansen, H. Fure, H. Qu, J. D. Lambris, B. Osterud, E. W. Nielsen, and T. E. Mollnes. 2013. The effects of selective complement and CD14 inhibition on the E. coli-induced tissue factor mRNA upregulation, monocyte tissue factor expression, and tissue factor functional activity in human whole blood. Adv. Exp. Med. Biol. 734: 123-136.
88. Karsten, C. M., M. K. Pandey, J. Figge, R. Kilchenstein, P. R. Taylor, M. Rosas, J. U. McDonald, S. J. Orr, M. Berger, D. Petzold, et al. 2012. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgRIIB and dectin-1. Nat. Med. 18: 1401-1406.
89. Ricklin, D., E. S. Reis, and J. D. Lambris. 2012. A sweet spot to control complement-induced inflammation. Nat. Med. 18: 1340-1341.
90. Sheen, T. R., C. K. Cavaco, C. M. Ebrahimi, M. L. Thoman, S. D. Sanderson, E. L. Morgan, and K. S. Doran. 2011. Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide. Vaccine 30: 9-13.
91. Morgan, E. L., B. N. Morgan, E. A. Stein, E. L. Vitrs, M. L. Thoman, S. D. Sanderson, and J. A. Phillips. 2009. Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design. Vaccine 28: 463-469.